AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Lantern Pharma Receives Buy Rating from Lake Street Analyst Chad Messer with a $25 Price Target
ByAinvest
Friday, Aug 15, 2025 8:04 pm ET1min read
Lantern Pharma (LTRN) received a Buy rating from Lake Street analyst Chad Messer, with a price target of $25.00. The company's shares closed at $4.57. Messer has an average return of -1.4% and a 38.32% success rate, covering the Healthcare sector. The analyst consensus on LTRN is a Moderate Buy with an average price target of $25.00.
Lake Street analyst Chad Messer has issued a Buy rating for Lantern Pharma (LTRN), with a price target of $25.00. The company's shares closed at $4.57 on July 02, 2025. Messer, known for his average return of -1.4% and a 38.32% success rate in the Healthcare sector, has a moderate Buy consensus on LTRN, with an average price target of $25.00.Lantern Pharma, a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform, reported strong financial results and operational highlights for the second quarter 2025. The company's drug candidates, LP-184 and LP-300, demonstrated significant clinical activity, with LP-184 achieving remarkable results in its Phase 1a trial and LP-300 showing a complete response in a 70-year-old patient with advanced non-small cell lung cancer (NSCLC).
The company's LP-284 drug candidate also exhibited remarkable clinical activity, achieving a complete metabolic response in a heavily pretreated patient with aggressive diffuse large B-cell lymphoma (DLBCL). These results position Lantern Pharma to advance its drug candidates into upcoming Phase 1b/2 studies and further clinical trials.
Lantern Pharma has also strengthened its global intellectual property portfolio, with the European Patent Office issuing a notice of allowance for a composition of matter patent covering LP-284. The company's AI algorithms hold five of the top eleven positions on the Therapeutic Data Commons Leaderboard, further enhancing its competitive edge in the market.
The analyst consensus on LTRN is a Moderate Buy, with an average price target of $25.00, reflecting the company's strong clinical pipeline, robust intellectual property portfolio, and promising AI-driven drug candidates.
References:
[1] https://www.biospace.com/press-releases/lantern-pharma-reports-second-quarter-2025-financial-results-and-business-updates
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet